Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Wholesale trade save search
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
Published: 2021-10-27 (Crawled : 14:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -1.2%
H: 2.85%
C: -2.03%
adhd
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 40.0%
H: 17.0%
C: -11.58%
treatment biopharma adhd
ABVC BioPharma Provides Vitargus® Update
Published: 2021-08-26 (Crawled : 13:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -2.03%
H: 30.71%
C: 19.09%
biopharma
ABVC BioPharma Report Updated by Zacks/SCR
Published: 2021-08-30 (Crawled : 13:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 16.54%
H: 2.52%
C: 0.32%
biopharma
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
Published: 2021-09-13 (Crawled : 16:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 4.05%
H: 0.53%
C: -10.18%
biopharma adhd
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 3.29%
H: 5.06%
C: -1.25%
abv-1505 biopharma conference adhd results
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
Published: 2022-06-16 (Crawled : 13:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -4.85%
H: 4.08%
C: -1.86%
vitargus biopharma australia
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
Published: 2022-06-21 (Crawled : 13:20) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 6.64%
H: 0.0%
C: 0.0%
partnership biopharma corporation
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
Published: 2022-09-23 (Crawled : 13:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 2.42%
H: 25.3%
C: 10.06%
biopharma adhd approval review update study
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
Published: 2022-11-14 (Crawled : 00:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 6.6%
H: 0.0%
C: -10.39%
biopharma financial results
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 13.03%
H: 0.05%
C: -9.47%
abv-1504 biopharma patent major depressive disorder
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma’s Medication for Treating Depression in Cancer Patients
Published: 2022-11-02 (Crawled : 13:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 0.0%
H: 6.21%
C: 4.83%
cancer depression study
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 3.45%
H: 10.33%
C: 2.67%
vitargus biopharma approval tga study
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
Published: 2022-09-09 (Crawled : 13:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -0.88%
H: 1.77%
C: -2.65%
vitargus biopharma study
ABVC Provides Oncology Pipeline Updates
Published: 2022-08-22 (Crawled : 13:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -0.77%
H: 4.25%
C: 4.25%
ABVC BioPharma Provides Vitargus® Update
Published: 2022-08-18 (Crawled : 13:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 4.08%
H: 18.76%
C: 14.93%
vitargus biopharma update
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
Published: 2022-08-15 (Crawled : 22:00) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 4.99%
H: 2.28%
C: 2.02%
biopharma results
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
Published: 2022-07-13 (Crawled : 13:20) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 2.94%
H: 0.63%
C: -5.9%
biopharma adhd update
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
Published: 2022-10-05 (Crawled : 16:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: 2.07%
H: 5.92%
C: 2.22%
vitargus biopharma australia approved study
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
Published: 2023-04-26 (Crawled : 14:00) - biospace.com/
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -4.9%
H: 10.04%
C: 3.72%
biopharma study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.